ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.5426T>A (p.Val1809Asp)

dbSNP: rs80357216
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001024087 SCV001186045 likely pathogenic Hereditary cancer-predisposing syndrome 2019-09-05 criteria provided, single submitter clinical testing The p.V1809D variant (also known as c.5426T>A), located in coding exon 21 of the BRCA1 gene, results from a T to A substitution at nucleotide position 5426. The valine at codon 1809 is replaced by aspartic acid, an amino acid with highly dissimilar properties. One functional study found that this nucleotide substitution is deleterious in a high throughput genome editing haploid cell survival assay (Findlay GM et al. Nature. 2018 10;562:217-222). Based on internal structural analysis, p.V1809D is highly disruptive to this region of BRCA1 (Ambry internal data; Gaiser OJ et al. Biochemistry. 2004 Dec;43(51):15983-95). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Brotman Baty Institute, University of Washington RCV001072912 SCV001238374 not provided Breast-ovarian cancer, familial, susceptibility to, 1 no assertion provided in vitro

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.